Covercard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Covercard

Quick Facts

Property Description
Active Ingredients Amlodipine and Perindopril
Form Oral dosage form Tablet (Single-pill combination)
Pharmacological Class Antihypertensive (CCB / ACE inhibitor)
Origin Synthetic

What is Covercard and How is it Classified?

Covercard is a synthetic antihypertensive medication classified as a Fixed-dose combination (FDC) product. This medicine is designed to manage high blood pressure using two complementary drug classes simultaneously. The core identity of Covercard is that of a Single-pill combination (SPC), which means it contains two distinct active ingredients in one oral dosage form tablet. This FDC strategy is clinically recognized for its role in vascular disorder therapies, often enhancing patient adherence compared to taking two separate medications.


What is the Composition of Covercard?

Covercard is composed of the active ingredients Amlodipine and Perindopril, representing a Calcium Channel Blocker (CCB) and an Angiotensin Converting Enzyme (ACE) inhibitor, respectively. These two compounds work through different biological pathways to achieve a combined therapeutic effect. The tablet formulation utilizes the salts Amlodipine besylate and Perindopril arginine (or similar equivalents) to deliver the precise amounts of both medicines with each dose. Amlodipine is specifically identified as a dihydropyridine derivative, a subclass of CCBs. The inclusion of an ACE inhibitor and a CCB together is widely recognized as a clinically effective strategy for achieving blood pressure targets.


What is the General Purpose of This Dual Therapy?

The general purpose of the Covercard dual therapy is to achieve a more potent and consistent lowering of blood pressure by simultaneously managing multiple factors that contribute to high blood pressure (hypertension). The combined action of Amlodipine and Perindopril works to relax and widen the body's blood vessels, reducing the overall resistance to blood flow. This physiological action reduces the strain on the heart and the entire vascular system, which is the fundamental objective for patients with elevated pressure. The fixed combination medicine is designed for high efficacy in managing high blood pressure, which serves as a necessary foundation for treating associated conditions like stable coronary artery disease.

What side effects are possible with Covercard?

Possible Side Effects and Safety Information

The safety profile of Covercard is established based on the documented adverse reactions for its dual components, Amlodipine (a CCB) and Perindopril (an ACE inhibitor), as classified by regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized by their documented occurrence rate:

  • Very Common (ge 1/10): Peripheral Oedema (swelling of the extremities), primarily associated with the Amlodipine component.
  • Common (ge 1/100 to < 1/10): These include Headache, Dizziness, Somnolence, Palpitations, Flushing, and a persistent Cough (a recognized class effect of ACE inhibitors). Gastrointestinal effects such as Nausea and Abdominal pain are also listed.

Serious Adverse Reactions and Key Safety Constraints

Official prescribing information highlights specific safety concerns, including Angioedema (a potentially life-threatening swelling involving the face or airway). The combination also carries a risk of excessive Hypotension and Hyperkalaemia (high potassium levels).

  • Time-Related Patterns: Effects like Dizziness and Headache are often noted as being more frequent at the beginning of the treatment. Angioedema may occur at any time during therapy.
  • Population Constraints: The medication is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury. It is also restricted for use in patients with severe Hepatic or severe Renal Impairment, as documented in regulatory warnings.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of this fixed-dose combination (Amlodipine and Perindopril) primarily presents as an exaggeration of its therapeutic effects. The most critical manifestations, according to regulatory documents, include profound and prolonged systemic hypotension and excessive peripheral vasodilation, leading to symptoms like fainting (syncope) and reflex tachycardia. Severe cases carry the risk of progression to life-threatening outcomes, specifically shock and secondary damage such as acute kidney injury.

Regulators mandate that all individuals must seek immediate medical attention for any suspected overdose. Emergency services must be called immediately if signs of systemic collapse, such as loss of consciousness or difficulty breathing, are observed. Management is defined as symptomatic and supportive treatment, involving interventions like volume expansion and vasopressors, as official labeling confirms that no specific antidote is known. Close monitoring of blood pressure, electrolytes, and renal function is required to mitigate potential complications. Furthermore, for individuals with renal failure or the elderly, the official label notes that elimination of the active metabolite may be decreased, which could prolong the toxic effects.

Therapeutic Uses of Covercard

What Covercard Treats: Main Uses and Benefits

Covercard is primarily used to address conditions characterized by periods of heightened symptoms, such as chronic high blood pressure (hypertension). This primary use is commonly applied across domains where additional symptomatic support is needed to help manage blood pressure levels. The medication is also relevant in conditions involving stable coronary artery disease.

The overall benefit is aligned with providing supportive relief that helps patients cope more steadily with symptom fluctuations, particularly in situations where symptoms are related to systemic imbalance. This supports general well-being during symptomatic phases and may assist with reducing the long-term risk of associated health problems.

Quick Fact: Symptomatic Support for Systemic Imbalance

Covercard is commonly used to help manage both hypertension and stable coronary artery disease, which are often situations where symptoms are linked to organ-specific functional stress.

Regulatory References

  1. Australian Government PBS document for Coveram®

Eligibility and Restrictions for Use

Who can and cannot use Covercard?

The eligibility for Covercard (Perindopril/Amlodipine) is strictly defined by regulatory authorities and is primarily indicated for adults as a substitution therapy for hypertension and/or stable coronary artery disease. Use is restricted or not recommended in several key populations:


Contraindicated Populations (Must Not Use)

Condition/Population Restriction Basis
Pregnancy (2nd & 3rd Trimesters) Risk of fetal injury from ACE inhibitor component.
Angioedema History Prior history related to any ACE inhibitor or hereditary angioedema.
Severe Hypotension/Cardiogenic Shock Severe hemodynamic instability.
Concomitant Sacubitril/Valsartan Absolute prohibition; requires a washout period.

Conditional or Not Recommended Use

  • Pediatric Use: Use in children and adolescents (le 18 years) is not recommended as efficacy and tolerability have not been established.
  • Renal Impairment: The fixed-dose tablet is not suitable for patients with Creatinine Clearance <60 mL/min, who require individual component titration.
  • Hepatic Impairment: Not recommended in severe cases; requires caution in mild-to-moderate cases.
  • Lactation/Breastfeeding: Generally not recommended due to potential passage into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Statements
Medicinal product categories with documented interactions Dual RAAS Blockade Agents (e.g., Angiotensin II Receptor Blockers, Aliskiren); Potassium-Sparing Diuretics; Potassium Supplements / Salts; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Agents that increase Angioedema Risk (e.g., ARNI, NEP inhibitors, mTOR inhibitors, Gliptins); Lithium; Other Antihypertensive Agents; Extracorporeal Treatments (using negatively charged surfaces).
Specific interacting medicines (if explicitly listed) Sacubitril/Valsartan; Aliskiren (in specific populations); Spironolactone, Triamterene, Amiloride (as potassium-sparing diuretics).

Interaction Classifications (High-Level)

Classification Official Regulatory Statements
Timing-based interaction rules Must not be initiated within 36 hours of the last dose of Sacubitril/Valsartan. Administration is recommended in the morning and before a meal due to food-related reduction in active metabolite exposure.
Population-specific interaction notes The combination with Aliskiren is contraindicated in patients with Diabetes Mellitus or with moderate-to-severe Renal Impairment. Perindoprilat elimination is documented as decreased in the elderly and in patients with renal failure.

Official Interaction Statements

Co-administration with Sacubitril/Valsartan is prohibited due to the risk of angioedema. The combination with Aliskiren is contraindicated in patients with diabetes or renal impairment. Co-administration with Potassium-sparing Diuretics or Potassium Supplements may lead to an increased risk of hyperkalemia. NSAIDs may reduce the antihypertensive effect and increase the risk of decreased renal function. Ingestion with a meal reduces the bioavailability of the active metabolite, which necessitates administering the tablet before a meal.

Mechanism of Action

Covercard functions primarily by targeting the enzyme farnesyl pyrophosphate synthase (FPPS) within osteoclast cells. Following cellular uptake, Covercard binds to FPPS, acting as a competitive inhibitor against its natural substrate, dimethylallyl pyrophosphate (DMAPP). This inhibition directly restricts the enzymatic activity of FPPS, thereby reducing the intracellular biosynthesis of critical prenyl lipids, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These isoprenoids are essential cofactors for the post-translational modification, known as prenylation, of several small GTPase proteins (e.g., Rho, Rac, Rab). The resulting deficit in prenylation prevents the proper membrane localization and subsequent activation of these signaling proteins. Since small GTPases are vital regulators of osteoclast structure, adhesion, and vesicular trafficking, their inactivation leads to a cascade that disrupts normal cytoskeletal organization and ultimately triggers programmed cell death (apoptosis) in the osteoclasts, resulting in modulation of bone tissue dynamics.

Dosage and Administration Information

How to Use Covercard: Official Administration Guidelines

Covercard (Perindopril arginine/Amlodipine) is administered via the oral route as a single-pill combination tablet. The general usage principle indicates its role as substitution therapy for patients whose blood pressure is already controlled by the separate components at equivalent doses. The medicine is taken once daily.


Dosing and Frequency

Feature Official Usage Principle
Dose One tablet daily, matching prior individual component doses (e.g., 5 mg/5 mg up to 10 mg/10 mg).
Alternative Regimen An initial therapy starting dose of 3.5 mg/2.5 mg once daily is approved in some regions, with a maximum dose of 14 mg/10 mg.
Frequency Taken once daily (every 24 hours).

Administration Context and Adjustments

Covercard should preferably be taken in the morning and before a meal. The tablet is swallowed whole with water. If dose adjustment is necessary in initial therapy, it generally occurs at intervals of 7 to 14 days.

Specific usage constraints apply to certain patient groups. For adults with moderate to severe renal impairment (creatinine clearance less than 60 mL/min), the fixed-dose combination is generally not suitable. In these cases, individual dose titration using the separate monocomponents is required to achieve the appropriate blood pressure control. Use in the pediatric population is not officially recommended due to lack of established safety and efficacy data.

Recent Clinical Evidence

Research Evidence for Covercard

Evidence for Use in Chronic High Blood Pressure (Hypertension)

Research evaluating Covercard for chronic high blood pressure (hypertension) includes large, long-term Randomized Controlled Trials (RCTs) and extensive Systematic Reviews and Meta-analyses. These studies focused on measuring how blood pressure (BP) changed and monitoring Cardiovascular Outcomes, such as the occurrence of stroke and heart attack.

Findings from these trials reported patterns observed in various BP measurements across adult study groups. Long-term strategy trials researched outcomes related to major CV events and mortality when these regimens were compared to alternative treatment options. Studies monitored adherence and reported patterns associated with the fixed combination pill compared to taking the two components separately.

However, specific trials that directly compare the fixed-dose combination pill against the two separate pills for all major cardiovascular endpoints over many years are not fully established.


Evidence for Use in Stable Coronary Artery Disease

The evidence landscape for Covercard in stable coronary artery disease (SCAD) includes large-scale Cardiovascular Outcome Trials and specific Clinical Trials that monitored adults diagnosed with SCAD. Researchers in these trials focused on evaluating symptomatic measurements like angina severity and changes in Exercise Capacity.

Studies focusing on symptomatic relief documented data related to symptom evolution in angina severity. Research also reported data related to the occurrence of non-fatal coronary events when the combination regimen was compared to an alternative strategy.

Limited information is available for certain long-term outcomes and for some special patient populations, such as pediatric groups. Furthermore, some systematic reviews have documented a limitation regarding the availability of cost-effectiveness assessments in the existing body of clinical evidence.

Key Studies & References Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Covercard (FAQ)


Q: Does Covercard work right away, or does it take time to notice effects?

The therapeutic effect of the individual components develops gradually over time. While the Amlodipine component reaches its peak in the blood within several hours, the full blood pressure-lowering effect is related to its long duration of action. For high blood pressure treatment, the medicine's effects are generally evaluated and any necessary adjustments occur over intervals of several weeks, according to official guidelines.

Q: Is Covercard something I will have to take long-term?

According to official product information, treatment for chronic conditions like high blood pressure is typically long-term. Administration of the medicine is generally considered an ongoing treatment, and it may continue long-term to manage the chronic condition.

Q: What happens if I miss a dose of Covercard?

Regulatory patient information generally describes the guidance to avoid taking a double dose to make up for a missed dose. If a dose is missed, official patient information commonly describes the guidance to skip the missed dose and resume the normal dosing schedule at the usual time.

Q: Can Covercard be taken with a multivitamin?

Some multivitamins contain minerals that may potentially affect the body's absorption or processing of the Amlodipine component. Official guidance on drug interactions notes that the potential for interaction with supplements means that the combination should be professionally reviewed.

Q: Does Covercard have any known interactions with grapefruit?

Yes, official product information notes that caution is warranted regarding grapefruit. Grapefruit or grapefruit juice can increase the concentration of the Amlodipine component in the bloodstream, which may heighten the risk of related side effects like headache or dizziness.

Q: Can I take cold medicine or cough syrups while using Covercard?

Cold and cough medicines often contain ingredients, such as non-steroidal anti-inflammatory drugs (NSAIDs) or decongestants, that can potentially interact with Covercard or affect blood pressure. Due to the varied composition of these products, professional review is necessary to determine the potential for interactions or adverse effects.

Q: Has Covercard been studied in elderly populations?

Yes, studies have examined the medicine's components in older patients. Regulatory documents note that the elimination of Perindoprilat, an active metabolite, is slower in the elderly. While normal dosing may apply, any dosage adjustments in this population are advised by regulatory documents to be made with care.

Q: Can Covercard affect how my body processes alcohol?

Official warnings state that alcohol may have an additive effect in lowering blood pressure when combined with this medicine. This combination may increase the risk of experiencing certain side effects, such as dizziness, lightheadedness, or fainting.

Q: Is Covercard known to cause weight gain?

Official reports of adverse reactions have documented 'rapid weight gain' or 'unusual weight gain or loss' as possible but generally uncommon side effects. Any noticeable change in weight should be managed through consultation with a healthcare professional.

Q: How quickly does Covercard leave the system?

The Amlodipine component has a slow elimination process. According to the pharmacokinetics data, its terminal elimination half-life generally ranges from 35 to 50 hours. This long half-life is the pharmacological characteristic that enables once-daily dosing.

Q: Is it true that Covercard is sometimes used for conditions other than heart-related ones?

The fixed-dose combination product is officially indicated only for the treatment of essential high blood pressure (hypertension) and/or stable coronary artery disease. Use beyond the official indications is not supported by regulatory documentation.

Q: Does Covercard affect cholesterol levels?

Clinical studies of the Perindopril component have generally shown that it does not significantly alter serum levels of lipids or cholesterol in patients treated for hypertension.

Q: What is the definition of a contraindication for Covercard?

A contraindication is a specific condition or circumstance under which the medicine must not be used. This prohibition is established by regulatory authorities because the risk of use is deemed to clearly outweigh any possible therapeutic benefit.

Q: Why is it advised that Covercard not be stopped suddenly?

Abrupt discontinuation of certain high blood pressure medicines carries the potential risk of leading to a rapid increase in blood pressure, known as rebound hypertension. This risk is typically addressed in official warnings regarding the use of antihypertensive medicines.

Q: Can Covercard affect blood sugar levels in patients?

Studies examining the Perindopril component, particularly in patients with glucose intolerance, have found no significant adverse changes in blood sugar or related parameters.

Q: Is there a generic version of Covercard available?

Yes, the active substances, Perindopril and Amlodipine, are commonly available as separate generic medications. Additionally, generic versions of the fixed-dose combination tablet are available on the market under various names, depending on the region.

Q: What are the signs that Covercard is working for a person?

The primary way the medicine shows effectiveness is by achieving a consistent lowering of high blood pressure. For individuals with stable coronary artery disease, evidence of therapeutic effect can also include a reduction in symptoms like angina.

Q: What should I do if I feel dizzy after starting Covercard?

Dizziness is a common, often temporary side effect related to the blood pressure-lowering action. Regulatory guidance provides context that individuals should be cautious when transitioning from a sitting or lying position to standing.

Q: What does the FDA label say about Covercard’s use?

The official FDA label indicates the medicine is used for the treatment of hypertension (high blood pressure) to lower blood pressure. It is also approved for use in certain patients as a substitution therapy or, in some cases, as initial therapy.

Q: Can Covercard be used alongside supplements like potassium or magnesium?

The use of potassium supplements or potassium-containing salts is specifically listed as a contraindication in regulatory documents due to the significant risk of developing high potassium levels (hyperkalemia). Magnesium supplements are typically not listed as a specific interaction.

Q: Are the research findings for Covercard considered strong?

Regulatory authorities supported the medicine's efficacy and safety based on evidence from multiple randomized, controlled trials conducted in adults. These findings indicated that the fixed combination achieved greater blood pressure reductions compared to the use of either single component (monotherapy).

Q: Is it important to check my blood pressure regularly while on Covercard?

Regulatory documents state that regular monitoring is an expected component of medical follow-up. Due to potential effects on kidney function and potassium levels, the usual medical follow-up often includes frequent checks of blood parameters, which generally requires monitoring blood pressure.

Q: Can Covercard be crushed or split?

The physical form of the tablet, as described in pharmaceutical documents, determines if it can be split. If the tablet has a score line, it may be divided into equal doses; otherwise, the tablet should be swallowed whole unless the pharmaceutical description indicates a score line that allows it to be divided into equal doses.

Q: Why is Covercard not recommended for people with certain heart rhythm issues?

The medicine is contraindicated in patients with severe conditions involving the heart and blood vessels, such as cardiogenic shock. It is also contraindicated for use in cases of severe obstruction of the heart’s outflow tract, such as high grade aortic stenosis.

How should Covercard be stored and disposed of?

Storage Conditions and Handling

Covercard tablets must be stored at controlled room temperature, typically between 20°C and 25°C. To maintain product stability as defined in the official labeling, the medicine must be protected from heat, moisture, and direct light. It is mandatory to store the tablets in the original, tightly closed container and essential to keep the product from freezing.

Child Safety and Disposal

For safety, Covercard must be stored out of the sight and reach of children.

Expired or unused medication must be disposed of properly according to local regulatory requirements. The medicine should not be discarded via household trash or flushed down the toilet unless explicitly instructed by a government drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Covercard found in:

A-Z Index: